GlassScriptPhysician profile
Eugene C Lozner
NPI 1083600779
$1,577.48
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,332 · 2020: $246.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $298.14 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $233.76 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $171.90 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.97 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $142.17 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $134.59 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $94.69 | 2019 | |
| Boston Scientific Corporation | $75.73 | 2019-2020 | |
| Amarin Pharma, INC. | $75.01 | 2019 | |
| Pfizer INC. | $65.00 | 2019-2020 | |
| Biotronik INC. | $31.44 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $27.40 | 2019 | |
| Edwards Lifesciences Corporation | $18.26 | 2019 | |
| Abbott Laboratories | $17.86 | 2019 | |
| Gilead Sciences, INC. | $12.62 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $11.94 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Lozner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.